NASDAQ · Financial Statements

Scribe Therapeutics Inc. (SCTX) Revenue, Earnings & Financial Statements

$15.77 NASDAQ: SCTX Market Cap $255.19M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Scribe Therapeutics Inc. most recently reported annual revenue of $51.0M, a net loss of $22.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Income Statement — 1 Years (USD millions)

Metric2025
Revenue$51.0M
Operating Expenses$77.0M
Operating Profit−$26.0M
Operating Margin-50.9%
Other Income$2.0M
Interest$2.0M
Depreciation$3.0M
Profit Before Tax−$24.0M
Tax rate (%)7.6%
Net Profit−$22.0M
EPS−$1.24

Quarterly Results — Last 3 Quarters (USD millions)

MetricMar '26Jun '26Sep '26
Revenue$2.0M$2.0M$2.0M
Operating Expenses$15.0M$11.0M$12.0M
Operating Profit−$12.0M−$9.0M−$11.0M
Operating Margin-556.5%-489.8%-663.9%
Interest$1.0M$0$0
Profit Before Tax−$17.0M−$6.0M−$10.0M
Tax rate (%)-1.3%-3.4%-2.4%
Net Profit−$17.0M−$6.0M−$10.0M
EPS−$7.05−$0.37−$0.52

Balance Sheet — 1 Years (USD millions)

Metric2025
Total Assets$78.0M
Current Assets$67.0M
Cash$13.0M
Inventory$0
Receivables$7.0M
Fixed Assets$10.0M
Capital Work in Progress$0
Investments$45.0M
Other Assets$0
Total Liabilities$101.0M
Current Liabilities$69.0M
Borrowings$41.0M
Other Liabilities$60.0M
Equity$0
Reserves−$23.0M

Cash Flow Statement — 1 Years (USD millions)

Metric2025
Operating Cash Flow−$45.0M
Investing Cash Flow$44.0M
Financing Cash Flow$0
Net Cash Flow$0
Free Cash Flow−$46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-3.19
FCF Yield-5.11%
Quick Ratio4.72
Interest Coverage-37.40
Return 1Y—
Return 3Y—
Return 5Y—

Scribe Therapeutics Inc. (SCTX) financials — frequently asked questions

What is Scribe Therapeutics Inc.'s annual revenue?

Scribe Therapeutics Inc. (SCTX) reported annual revenue of $51.0M in its most recent fiscal year.

What is Scribe Therapeutics Inc.'s net profit?

Scribe Therapeutics Inc. (SCTX) reported a net loss of $22.0M in its most recent fiscal year.

What is SCTX EV/EBITDA?

Scribe Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -3.19. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
SCTX Overview SCTX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.